Skip to content
2000
image of Potential Indicators for the Development of Hepatocellular Carcinoma: A Diagnostic Strategy

Abstract

: Hepatocellular carcinoma (HCC), a primary malignancy of the liver, ranks among the top five most common cancers globally and is associated with high mortality due to its poor prognosis, late-stage detection, and limited therapeutic success. Early diagnosis is essential to improve treatment outcomes and survival rates. Biomarkers have emerged as vital tools for the early detection, prognosis, and therapeutic monitoring of HCC, with many detectable in serum or urine at quantifiable levels. These biomarkers may be overexpressed, downregulated, or involved in regulatory pathways affecting other proteins and molecules, thereby serving as potential indicators of tumor development. This review aims to provide an updated overview of promising HCC biomarkers, highlighting their diagnostic value and clinical utility. A structured literature search was conducted using PubMed, Scopus, and Web of Science databases for studies published. Eligible studies were selected based on predefined inclusion criteria, evaluated for quality, and thematically categorized according to the type and function of biomarkers. The review emphasizes the translational potential of these indicators in developing more effective diagnostic strategies for HCC.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266349627250626142221
2025-07-16
2025-09-13

  • From This Site

    /content/journals/ctmc/10.2174/0115680266349627250626142221
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Liu C.Y. Chen K.F. Chen P.J. Treatment of liver cancer. Cold Spring Harb. Perspect. Med. 2015 5 9 a021535 10.1101/cshperspect.a021535 26187874
    [Google Scholar]
  2. Woo H.Y. Heo J. Sorafenib in liver cancer. Expert Opin. Pharmacother. 2012 13 7 1059 1067 10.1517/14656566.2012.679930 22519770
    [Google Scholar]
  3. Anwanwan D. Singh S.K. Singh S. Saikam V. Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA)-. Rev. Can. 2020 1873 1 188314
    [Google Scholar]
  4. Henry S.H. Bosch F.X. Foodborne disease and mycotoxin epidemiology. Foodborne Disease Handbook. CRC Press 2019 593 626 10.1201/9781351072090‑14
    [Google Scholar]
  5. Kew M.C. Song E. Mohammed A. Hodkinson J. Contraceptive steroids as a risk factor for hepatocellular carcinoma: a case/control study in South African black women. Hepatology 1990 11 2 298 302 10.1002/hep.1840110221 2155169
    [Google Scholar]
  6. Chen C. Wang G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J. Hepatol. 2015 7 15 1964 1970 10.4254/wjh.v7.i15.1964 26244070
    [Google Scholar]
  7. Saffroy R. Pham P. Reffas M. Takka M. Lemoine A. Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin. Chem. Lab. Med. 2007 45 9 1169 1179 10.1515/CCLM.2007.262
    [Google Scholar]
  8. Galicia-Moreno M. Silva-Gomez J.A. Lucano-Landeros S. Santos A. Monroy-Ramirez H.C. Liver cancer: therapeutic challenges and the importance of experimental models. Can. J. Gastroenterol. Hepatol. 2021 2021 8837811 10.1515/CCLM.2007.262
    [Google Scholar]
  9. Piñero F. Dirchwolf M. Pessôa M.G. Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells 2020 9 6 1370 10.3390/cells9061370 32492896
    [Google Scholar]
  10. Trovato F.M. Tognarelli J.M. Crossey M.M. Catalano D. Taylor-Robinson S.D. Trovato G.M. Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World J. Hepatol. 2015 7 26 2664 2675 10.4254/wjh.v7.i26.2664 26609343
    [Google Scholar]
  11. De Stefano F. Chacon E. Turcios L. Marti F. Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig. Liver Dis. 2018 50 11 1115 1123 10.1016/j.dld.2018.08.019 30217732
    [Google Scholar]
  12. Chaiteerakij R. Addissie B.D. Roberts L.R. Update on biomarkers of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2015 13 2 237 245 10.1016/j.cgh.2013.10.038 24275343
    [Google Scholar]
  13. Lou J. Zhang L. Lv S. Zhang C. Jiang S. Biomarkers for hepatocellular carcinoma. Biomark. Cancer 2017 9 1 9 10.1177/1179299X16684640
    [Google Scholar]
  14. Zacharakis G. Aleid A. Aldossari K.K. New and old biomarkers of hepatocellular carcinoma. Hepatoma Res. 2018 4 10 65 10.20517/2394‑5079.2018.76
    [Google Scholar]
  15. Oh J.H. Jun D.W. The latest global burden of liver cancer: A past and present threat. Clin. Mol. Hepatol. 2023 29 2 355 357 10.3350/cmh.2023.0070 36891606
    [Google Scholar]
  16. [https://www.wcrf.org/cancer-trends/liver-cancer-statistics/
  17. Rumgay H. Arnold M. Ferlay J. Lesi O. Cabasag C.J. Vignat J. Laversanne M. McGlynn K.A. Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 2022 77 6 1598 1606 10.1016/j.jhep.2022.08.021 36208844
    [Google Scholar]
  18. McMahon B.J. Bulkow L.R. Singleton R.J. Williams J. Snowball M. Homan C. Parkinson A.J. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011 54 3 801 807 10.1002/hep.24442 21618565
    [Google Scholar]
  19. Cramp M.E. Rosenberg W.M. Ryder S.D. Blach S. Parkes J. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol. 2014 14 1 137 10.1186/1471‑230X‑14‑137 25100159
    [Google Scholar]
  20. Liu Y. Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment. Environ. Health Perspect. 2010 118 6 818 824 10.1289/ehp.0901388 20172840
    [Google Scholar]
  21. Rumgay H. Shield K. Charvat H. Ferrari P. Sornpaisarn B. Obot I. Islami F. Lemmens V.E.P.P. Rehm J. Soerjomataram I. Global burden of cancer in 2020 attributable to alcohol consumption: A population-based study. Lancet Oncol. 2021 22 8 1071 1080 10.1016/S1470‑2045(21)00279‑5 34270924
    [Google Scholar]
  22. Kontomanolis E.N. Koutras A. Syllaios A. Schizas D. Mastoraki A. Garmpis N. Diakosavvas M. Angelou K. Tsatsaris G. Pagkalos A. Ntounis T. Fasoulakis Z. Role of oncogenes and tumor-suppressor genes in carcinogenesis: A review. Anticancer Res. 2020 40 11 6009 6015 10.21873/anticanres.14622 33109539
    [Google Scholar]
  23. Singh A.K. Kumar R. Pandey A.K. Hepatocellular carcinoma: Causes, mechanism of progression and biomarkers. Curr. Chem. Genomics Transl. Med. 2018 12 1 9 26 10.2174/2213988501812010009 30069430
    [Google Scholar]
  24. Henley S.A. Dick F.A. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div. 2012 7 1 10 10.1186/1747‑1028‑7‑10 22417103
    [Google Scholar]
  25. Michalopoulos G.K. Liver regeneration after partial hepatectomy: Critical analysis of mechanistic dilemmas. Am. J. Pathol. 2010 176 1 2 13 10.2353/ajpath.2010.090675 20019184
    [Google Scholar]
  26. Liu H. Luan F. Ju Y. Shen H. Gao L. Wang X. Liu S. Zhang L. Sun W. Ma C. In vitro transfection of the hepatitis B virus PreS2 gene into the human hepatocarcinoma cell line HepG2 induces upregulation of human telomerase reverse transcriptase. Biochem. Biophys. Res. Commun. 2007 355 2 379 384 10.1016/j.bbrc.2007.01.160 17307151
    [Google Scholar]
  27. Alqahtani A. Khan Z. Alloghbi A. Said Ahmed T.S. Ashraf M. Hammouda D.M. Hepatocellular carcinoma: Molecular mechanisms and targeted therapies. Medicina (Kaunas) 2019 55 9 526 10.3390/medicina55090526 31450841
    [Google Scholar]
  28. Okano H. Shiraki K. Inoue H. Kawakita T. Yamanaka T. Deguchi M. Sugimoto K. Sakai T. Ohmori S. Fujikawa K. Murata K. Nakano T. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab. Invest. 2003 83 7 1033 1043 10.1097/01.LAB.0000079328.76631.28 12861043
    [Google Scholar]
  29. Xu M. Yu Q. Subrahmanyam R. Difilippantonio M.J. Ried T. Sen J.M. β-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo. Mol. Cell. Biol. 2008 28 5 1713 1723 10.1128/MCB.01360‑07 18160717
    [Google Scholar]
  30. Kaposi-Novak P. Libbrecht L. Woo H.G. Lee Y.H. Sears N.C. Conner E.A. Factor V.M. Roskams T. Thorgeirsson S.S. Thorgeirsson S.S. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 2009 69 7 2775 2782 10.1158/0008‑5472.CAN‑08‑3357 19276364
    [Google Scholar]
  31. Chunhua Z. Clinical significance of α-fetoprotein in initial diagnosis of primary hepatic cancer. J. Clin. Hepatol. 2013 39 9
    [Google Scholar]
  32. Song P. Tang Q. Feng X. Tang W. Biomarkers: Evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scand. J. Clin. Lab. Invest. Suppl. 2016 245 S70 10.1080/00365513.2016.1210328
    [Google Scholar]
  33. Nakatsura T. Yoshitake Y. Senju S. Monji M. Komori H. Motomura Y. Hosaka S. Beppu T. Ishiko T. Kamohara H. Ashihara H. Katagiri T. Furukawa Y. Fujiyama S. Ogawa M. Nakamura Y. Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun. 2003 306 1 16 25 10.1016/S0006‑291X(03)00908‑2 12788060
    [Google Scholar]
  34. Marrero J.A. Su G.L. Wei W. Emick D. Conjeevaram H.S. Fontana R.J. Lok A.S. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003 37 5 1114 1121 10.1053/jhep.2003.50195 12717392
    [Google Scholar]
  35. Ince V. Carr B.I. Bag H.G. Koc C. Usta S. Ersan V. Baskiran A. Sahin T.T. Yilmaz S. Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with 5 cm tumors, treated by liver transplantation. Int. J. Biol. Markers 2020 35 2 91 95 10.1177/1724600820921869 32436751
    [Google Scholar]
  36. Mossad N.A. Mahmoud E.H. Osman E.A. Mahmoud S.H. Shousha H.I. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-l-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma. Tumour Biol. 2014 35 11 11559 11564 10.1007/s13277‑014‑2467‑y 25129443
    [Google Scholar]
  37. Liu S. Ma L. Huang W. Shai Y. Ji X. Ding L. Liu Y. Yu L. Zhao S. Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma. Cell. Mol. Biol. Lett. 2006 11 2 230 241 10.2478/s11658‑006‑0022‑6 16847567
    [Google Scholar]
  38. Mao Y. Yang H. Xu H. Lu X. Sang X. Du S. Zhao H. Chen W. Xu Y. Chi T. Yang Z. Cai J. Li H. Chen J. Zhong S. Mohanti S.R. Lopez-Soler R. Millis J.M. Huang J. Zhang H. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010 59 12 1687 1693 10.1136/gut.2010.214916 20876776
    [Google Scholar]
  39. Lin T.H. Shao Y.Y. Chan S.Y. Huang C.Y. Hsu C.H. Cheng A.L. High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib. Clin. Cancer Res. 2015 21 16 3678 3684 10.1158/1078‑0432.CCR‑14‑1954 25977342
    [Google Scholar]
  40. Kim J.U. Shariff M.I.F. Crossey M.M.E. Gomez-Romero M. Holmes E. Cox I.J. Fye H.K.S. Njie R. Taylor-Robinson S.D. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J. Hepatol. 2016 8 10 471 484 10.4254/wjh.v8.i10.471 27057305
    [Google Scholar]
  41. Huang P. Xu X. Wang L. Zhu B. Wang X. Xia J. The role of EGF ‐ EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J. Cell. Mol. Med. 2014 18 2 218 230 10.1111/jcmm.12153 24268047
    [Google Scholar]
  42. Ren Y. Cao B. Law S. Xie Y. Lee P.Y. Cheung L. Chen Y. Huang X. Chan H.M. Zhao P. Luk J. Vande Woude G. Wong J. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: A prognostic marker of human esophageal squamous cell carcinomas. Clin. Cancer Res. 2005 11 17 6190 6197 10.1158/1078‑0432.CCR‑04‑2553 16144920
    [Google Scholar]
  43. El-Assal O.N. Yamanoi A. Ono T. Kohno H. Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 2001 7 5 1299 1305 11350898
    [Google Scholar]
  44. Debruyne E.N. Delanghe J.R. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications. Clin. Chim. Acta 2008 395 1-2 19 26 10.1016/j.cca.2008.05.010 18538135
    [Google Scholar]
  45. Lv H. Gao J. Lu Y. Sun X. Zheng K. Zhang P. Ding C. Simultaneous targeted analysis of GGT and Its H-Type mRNA in HepG2 cells based on degradable silicon nanomaterials. Anal. Chem. 2021 93 49 16581 16589 10.1021/acs.analchem.1c03911 34854293
    [Google Scholar]
  46. Lin N. Li J. Ke Q. Wang L. Cao Y. Liu J. Clinical significance of C-reactive protein to albumin ratio in patients with hepatocellular carcinoma: A meta-analysis. Dis. Markers 2020 202 4867974 10.1155/2020/4867974
    [Google Scholar]
  47. Jin Y. Wong Y.S. Goh B.K.P. Chan C.Y. Cheow P.C. Chow P.K.H. Lim T.K.H. Goh G.B.B. Krishnamoorthy T.L. Kumar R. Ng T.P. Chong S.S. Tan H.H. Chung A.Y.F. Ooi L.L.P.J. Chang J.P.E. Tan C.K. Lee C.G.L. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci. Rep. 2019 9 1 10464 10.1038/s41598‑019‑46872‑8 31320713
    [Google Scholar]
  48. Jabbour T.E. Lagana S.M. Lee H. Update on hepatocellular carcinoma: Pathologists’ review. World J. Gastroenterol. 2019 25 14 1653 1665 10.3748/wjg.v25.i14.1653 31011252
    [Google Scholar]
  49. Galle P.R. Forner A. Llovet J.M. Mazzaferro V. Piscaglia F. Raoul J-L. Schirmacher P. Vilgrain V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018 69 1 182 236 10.1016/j.jhep.2018.03.019 29628281
    [Google Scholar]
  50. Forner A. Reig M. Bruix J. Hepatocellular carcinoma. Lancet 2018 391 10127 1301 1314 10.1016/S0140‑6736(18)30010‑2 29307467
    [Google Scholar]
  51. Gupta S. Bent S. Kohlwes J. Roberts J.P. Alpha-fetoprotein screening for hepatocellular carcinoma: A reappraisal. J. Hepatol. 2021 74 6 1408 1420
    [Google Scholar]
  52. Zheng P. Xu D. Cai Y. Zhu L. Xiao Q. Peng W. Chen B. A multi-omic analysis reveals that Gamabufotalin exerts anti-hepatocellular carcinoma effects by regulating amino acid metabolism through targeting STAMBPL1. Phytomedicine 2024 135 156094 10.1016/j.phymed.2024.156094 39348778
    [Google Scholar]
  53. Gao T.H. Liao W. Lin L.T. Zhu Z.P. Lu M.G. Fu C.M. Xie T. Curcumae rhizoma and its major constituents against hepatobiliary disease: Pharmacotherapeutic properties and potential clinical applications. Phytomedicine 2022 102 154090 10.1016/j.phymed.2022.154090 35580439
    [Google Scholar]
  54. Shen Y. Cheng L. Xu M. Wang W. Wan Z. Xiong H. Guo W. Cai M. Xu F. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. Metabolism 2023 146 155657 10.1016/j.metabol.2023.155657 37422021
    [Google Scholar]
  55. Chen L. He Y. Zhu J. Zhao S. Qi S. Chen X. Zhang H. Ni Z. Zhou Y. Chen G. Liu S. Xie T. The roles and mechanism of m6A RNA methylation regulators in cancer immunity. Biomed. Pharmacother 2023 163 114839 10.1016/j.biopha.2023.114839
    [Google Scholar]
  56. Yin D. Zhong Y. Ling S. Lu S. Wang X. Jiang Z. Wang J. Dai Y. Tian X. Huang Q. Wang X. Chen J. Li Z. Li Y. Xu Z. Jiang H. Wu Y. Shi Y. Wang Q. Xu J. Hong W. Xue H. Yang H. Zhang Y. Da L. Han Z. Tao S. Dong R. Ying T. Hong J. Cai Y. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat. Biomed. Eng. 2024 9 2 185 200 10.1038/s41551‑024‑01208‑4 38714892
    [Google Scholar]
  57. Best J. Bechmann L.P. Sowa J.P. Sydor S. Dechêne A. Pflanz K. Bedreli S. Schotten C. Geier A. Berg T. Fischer J. Vogel A. Bantel H. Weinmann A. Schattenberg J.M. Huber Y. Wege H. von Felden J. Schulze K. Bettinger D. Thimme R. Sinner F. Schütte K. Weiss K.H. Toyoda H. Yasuda S. Kumada T. Berhane S. Wichert M. Heider D. Gerken G. Johnson P. Canbay A. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic Steatohepatitis. Clin. Gastroenterol. Hepatol. 2020 18 3 728 735.e4 10.1016/j.cgh.2019.11.012 31712073
    [Google Scholar]
  58. Johnson P.J. Berhane S. Ahern E. Teng M. GALAD in the detection of hepatocellular carcinoma: A large-scale international validation study. Hepatology 2020 74 5 2220 2231
    [Google Scholar]
  59. Yu W.M. Li G.W. Lou M.G. Wu Z.Y. A meta-analysis of the prognostic impact of tissue golgi protein 73 (tGP73) in hepatocellular carcinoma. BMC Gastroenterol. 2023 23 1 401 10.1186/s12876‑023‑03050‑5 37978447
    [Google Scholar]
  60. Jiang D. Zhang Y. Wang Y. Xu F. Liang J. Wang W. Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: A systematic review and meta-analysis. Front. Oncol. 2022 12 1012418 10.3389/fonc.2022.1012418 36212469
    [Google Scholar]
  61. Shen J. Wang Y. Zheng F. Clinical performance of serum biomarkers GP73 and AFP in diagnosing hepatocellular carcinoma: A retrospective study. J. Hematol. Res. 2021 10 2 150 161
    [Google Scholar]
  62. Zhang B. Zhu B. Yu J. Liu H. Zhou Y. Sun G. Ma Y. Luan Y. Chen M. A combined model of six serum microRNAs as diagnostic markers for hepatocellular carcinoma. Clin. Chim. Acta 2025 565 119977 10.1016/j.cca.2024.119977 39332657
    [Google Scholar]
  63. Zhang B. Ma X. Zhou Y. Zhu B. Yu J. Liu H. Ma Y. Luan Y. Chen M. Diagnostic value of circulating microRNAs for hepatocellular carcinoma: Results of a meta-analysis and validation. Biochem. Genet. 2025 10.1007/s10528‑024‑11001‑2 39751721
    [Google Scholar]
/content/journals/ctmc/10.2174/0115680266349627250626142221
Loading
Potential Indicators for the Development of Hepatocellular Carcinoma: A Diagnostic Strategy
Bentham Science Publishers ; https://doi.org/10.2174/0115680266349627250626142221
/content/journals/ctmc/10.2174/0115680266349627250626142221
/content/journals/ctmc/10.2174/0115680266349627250626142221
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: metastasis ; Hepatocellular carcinoma ; miRNA ; Apoptosis ; Biomarkers

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test